Major Spanish hospital uses Syngene system for Western blot imaging
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to announce a Syngene multi-application imager is being used by scientists at a major hospital in Spain to accelerate Western blot analysis of proteins expressed by white blood cells post-vaccination.
Researchers at the hospital in Spain are using the Syngene system to rapidly and accurately analyse ECL labelled chemiluminescent Western blots of cellular receptors and proteins expressed by neutrophil and leukocyte white blood cells. This fundamental research is allowing the scientists to detect changes in protein expression post-vaccination and is providing information to make predictions about the efficacy of, and potential adverse events associated with clinical vaccines.
The Syngene system at the hospital is also fitted with a UV transilluminator and green, blue and IR LED lighting as the researchers also currently use the system to visualise Ethidium bromide stained DNA gels and may in future image and analyse fluorescent multiplex Western blots.
A pharmacist at the hospital said: “After vaccination we need to see which proteins are being expressed to determine the efficacy and safety profile of a vaccine. As part of this research we work with chemiluminescent Western blots, but we don’t want to image our results using X-ray film as this is time consuming and difficult.”
The pharmacist added: “In 2015, we installed a Syngene imager because scientists from other laboratories recommended the system. My colleague and I have found the system to be a very good device and easy to use. A major advantage for us now is that we obtain results much more rapidly than using X-ray film.”
“We’re delighted to hear that our imaging system is being used to speed up vital research at a major Spanish hospital,” stated Dr Martin Biggs, Sales Manager at Syngene. “Their work is a great endorsement of how this innovative imaging technology can be used in an immunology laboratory to improve the throughput and quality of vaccine testing.”